Efficacy
death, HL, Cemi, PTCL, DLBCL, cHL, peripheral T‐cell lymphoma
LYMPHOMA, CLASSIC HODGKIN LYMPHOMA, CHL, HODGKIN'S LYMPHOMA
Among the all‐treated population, response rate was 55.6%, 33.3%, 5.9%, and 9.1% in cHL anti‐PD‐1/PD‐L1 naïve, cHL anti‐PD‐1/PD‐L1 progressor, DLBCL, and PTCL cohorts, respectively (Table Summary of response rate per Lugano 2014 criteria, all‐treated population
Abbreviations: cHL, classic Hodgkin's lymphoma; CR, complete response; DLBCL, diffuse large B‐cell lymphoma; PD‐1, programmed death‐1; PD‐L1, programmed death ligand‐1; PR, partial response; PTCL, peripheral T‐cell lymphoma.Including patients with no post‐baseline evaluation prior to the initiation of a new anti‐cancer therapy or the data cutoff date.Median PFS (95% CI) was 8.38 months (2.73–not calculable [NC]), 8.28 months (2.60–NC), 2.37 months (0.46–2.69), and 2.66 months (0.43–2.99) in cHL anti‐PD‐1/PD‐L1 naïve, cHL anti‐PD‐1/PD‐L1 progressors, DLBCL, and PTCL cohorts, respectively (Figure Progression‐free survival (PFS): Kaplan–Meier estimates by cohort, all‐treated population. Cemi, cemiplimab; cHL, classic Hodgkin lymphoma (HL); DLBCL, diffuse large B‐cell lymphoma; PD‐1, programmed death‐1; PD‐L1, programmed death ligand‐1; PTCL, peripheral T‐cell lymphoma; Isa, isatuximab